ArticleStem cell research & therapy2020
Quantification of the CM-Dil-labeled human umbilical cord mesenchymal stem cells migrated to the dual injured uterus in SD rat.
Article in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Meta-analysis of mesenchymal stem cell therapy for intrauterine adhesions: a comprehensive consideration of efficacy and safety.Frontiers in bioengineering and biotechnology · 2025Pooled it
- Impact of intrauterine infusion of human umbilical cord blood mononuclear cells on reproductive outcomes in patients with thin endometrium undergoing frozen embryo transfer.Frontiers in cell and developmental biology · 2026Article
- Mesenchymal stem cells: opening a new chapter in the treatment of gynecological diseases.Stem cell research & therapy · 2025Review
- Microencapsulated 3D culture of human umbilical cord-derived mesenchymal stem cells enhances their therapeutic effect on intrauterine adhesion.Stem cells translational medicine · 2025Article
- Transcriptomics and proteomics reveal associations between myometrium and intrauterine adhesions.BMC women's health · 2025Article
- Innovative therapeutic strategies for intrauterine adhesions: Role of umbilical cord mesenchymal stem cells in rat models.Experimental and therapeutic medicine · 2025Article
- Advances in human umbilical cord mesenchymal stem cells-derived extracellular vesicles and biomaterial assemblies for endometrial injury treatment.World journal of stem cells · 2025Review
- A temperature responsive hydrogel encapsulated with adipose-derived stem cells and melanin promotes repair and regeneration of endometrial injury.Bioengineering & translational medicine · 2025Article
- Application of biomaterials in mesenchymal stem cell based endometrial reconstruction: current status and challenges.Frontiers in bioengineering and biotechnology · 2025Review
- Oligodendrocyte Progenitor Cell Transplantation Reduces White Matter Injury in a Fetal Goat Model.CNS neuroscience & therapeutics · 2024Article
- Characterization of CM-Dil-labeled Muse cells in culture and in skin wounds in rats.Cell and tissue banking · 2024Article
- Novel therapeutic targets, including IGFBP3, of umbilical cord mesenchymal stem-cell-conditioned medium in intrauterine adhesion.Biology open · 2024Article
- Endometrial mesenchymal stromal/stem cells improve regeneration of injured endometrium in mice.Biological research · 2024Article
- The Combination of Super-Active Platelet Lysate and Acellular Amniotic Membrane Enhances Endometrial Receptivity, While Simultaneously Facilitating Endometrial Repair in Rats.Journal of inflammation research · 2024Article
- Mesenchymal stem cell secretome alters gene expression and upregulates motility of human endometrial stromal cells.Reproduction (Cambridge, England) · 2023Article
- Repairing and Regenerating Injured Endometrium Methods.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- Evaluation of different rat models intrauterine adhesion models and improvement of the technique for their establishment.Experimental animals · 2023Article
- Human Umbilical Cord-Based Therapeutics: Stem Cells and Blood Derivatives for Female Reproductive Medicine.International journal of molecular sciences · 2022Review
- Research progress of stem cell therapy for endometrial injury.Materials today. Bio · 2022Review
- Bi-potential hPSC-derived Müllerian duct-like cells for full-thickness and functional endometrium regeneration.NPJ Regenerative medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman umbilical cord mesenchymal stem cell (hUC-MSC) therapy is considered as a promising approach in the treatment of intrauterine adhesions (IUAs). Considerable researches have already detected hUC-MSCs by diverse methods. This paper aims at exploring the quantitative distribution of CM-Dil-labeled hUC-MSCs in different regions of the uterus tissue of the dual injury-induced IUAs in rats and the underlying mechanism of restoration of fertility after implantation of hUC-MSCs in the IUA model.
methodsIn this study, we investigated the quantification of the CM-Dil-labeled hUC-MSCs migrated to the dual injured uterus in Sprague Dawley rats. Additionally, we investigated the differentiation of CM-Dil-labeled hUC-MSCs. The differentiation potential of epithelial cells, vascular endothelial cells, and estrogen receptor (ER) cells were assessed by an immunofluorescence method using CK7, CD31, and ERα. The therapeutic impact of hUC-MSCs in the IUA model was assessed by hematoxylin and eosin, Masson, immunohistochemistry staining, and reproductive function test. Finally, the expression of TGF-β1/Smad3 pathway in uterine tissues was determined by qRT-PCR and Western blotting.
resultsThe CM-Dil-labeled cells in the stroma region were significantly higher than those in the superficial myometrium (SM) (71.67 ± 7.98 vs. 60.92 ± 3.96, p = 0.005), in the seroma (71.67 ± 7.98 vs. 23.67 ± 8.08, p = 0.000) and in the epithelium (71.67 ± 7.98 vs. 4.17 ± 1.19, p = 0.000). From the 2nd week of treatment, hUC-MSCs began to differentiate into epithelial cells, vascular endothelial cells, and ER cells. The therapeutic group treated with hUC-MSCs exhibited a significant decrease in fibrosis (TGF-β1/Smad3) as well as a significant increase in vascularization (CD31) compared with the untreated rats.
conclusionOur findings suggested that the distribution of the migrated hUC-MSCs in different regions of the uterine tissue was unequal. Most cells were in the stroma and less were in the epithelium of endometrium and gland. Injected hUC-MSCs had a capacity to differentiate into epithelial cells, vascular endothelial cells, and ER cells; increase blood supply; inhibit fibration; and then restore the fertility of the IUA model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.